clinical trial · NCT07539441
A Study of Mirdametinib in People With Central Nervous System Tumors
Central Nervous System TumorsGliomaMirdametinib
brief summary
The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).
started
Apr 10, 2026
primary completion
Oct 10, 2029
completion
Oct 10, 2029
last updated
Apr 27, 2026
official title
Phase 1/2 Trial of Mirdametinib in Patients With MAPK Pathway Mutant Central Nervous System Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol